Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.

Reif A., ANIL YAĞCIOĞLU A. E., Luts A., Messer T., Nielsen R., Buyze J., ...Daha Fazla

31st European Congress of Psychiatry (EPA), Paris, Fransa, 25 Mart 2023

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Paris
  • Basıldığı Ülke: Fransa
  • Hacettepe Üniversitesi Adresli: Evet